- Home
- BLFS vs PVLA Comparison
BLFS vs PVLA Comparison
Compare BLFS & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLFS | PVLA |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2013 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BLFS | PVLA |
|---|---|---|
| Price | $38.77 | $131.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $31.29 | ★ $230.53 |
| AVG Volume (30 Days) | ★ 856.3K | 169.8K |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.27 | 52.62 |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $96,214,000.00 | $42,810,000.00 |
| Revenue This Year | $19.76 | N/A |
| Revenue Next Year | $17.03 | N/A |
| P/E Ratio | $39.13 | ★ N/A |
| Revenue Growth | 16.97 | ★ 65.28 |
| 52 Week Low | $17.86 | $65.93 |
| 52 Week High | $39.76 | $161.38 |
Technical Indicators
Market Signals| Indicator | BLFS | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 59.48 | 32.50 |
| Support Level | $34.38 | $109.68 |
| Resistance Level | N/A | $135.23 |
| Average True Range (ATR) | 1.10 | 6.28 |
| MACD | -0.01 | -2.26 |
| Stochastic Oscillator | 72.24 | 7.31 |
Price Performance
Historical ComparisonAbout BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.